Edge Wealth Management’s ImmunityBio IBRX Stock Holding History

Edge Wealth Management’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-20,000	Closed	-$21K	–	620
2019 Q2	$21K	Hold	20,000	–	–	﹤0.01%	331
2019 Q1	$32K	Buy	20,000 +10,000	+100%	+$12.6K	0.01%	280
2018 Q4	$12K	Buy	+10,000	New	+$22.9K	﹤0.01%	380
2017 Q4	–	Sell	-10,000	Closed	-$55K	–	551
2017 Q3	$55K	Buy	+10,000	New	+$61.6K	0.02%	214
2016 Q1	–	Sell	-500	Closed	-$9K	–	476
2015 Q4	$9K	Hold	500	–	–	﹤0.01%	302
2015 Q3	$6K	Buy	+500	New	+$10.9K	﹤0.01%	331

Other funds holding IBRX

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WCM

Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HKAM

Horizon Kinetics Asset Management New York $9.23B AUM 27.52% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Edge Wealth Management's IBRX Position: Q3 2019 in Review

Edge Wealth Management sold out of ImmunityBio (IBRX) in Q3 2019, closing a stake of 20,000 shares — an estimated $21K sold.

Edge Wealth Management first reported a position in IBRX in Q3 2015 and held it in 6 quarters. The position peaked at $55K in Q3 2017. 39 funds tracked by Wall St. Rank hold IBRX as of Q3 2019.

Edge Wealth Management reported no remaining ImmunityBio position as of Q3 2019 after selling out during the quarter.
Edge Wealth Management sold 20,000 ImmunityBio shares in Q3 2019, an estimated $21K.
Edge Wealth Management first reported a position in ImmunityBio in Q3 2015 and held it in 6 quarters.
Edge Wealth Management's ImmunityBio position peaked at $55K in Q3 2017.
39 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2019.

Based on Edge Wealth Management's 13F filing for Q3 2019, filed 21 Oct 2019.